Type III phosphodiesterase plays a necessary role in the growth-promoting actions of insulin, insulin-like growth factor-I, and Ha p21ras in Xenopus laevis oocytes.
Three phosphodiesterase (PDE) type III inhibitors were tested and found to inhibit Xenopus oocyte maturation induced by insulin with apparent IC50 values of 2.2 +/- 0.2 microM Cl-930, 25 +/- 3 microM imazodan (Cl-914), and 786 +/- 237 microM piroximone (MDL 19,205). The same rank order of potencies was observed for inhibition of insulin-like growth factor-I (IGF-I)-induced oocyte maturation, with IC50 values of 5.5 +/- 0.9 microM Cl-930, 54 +/- 4 microM imazodan, and 1190 +/- 395 microM piroximone. Oocyte maturation induced by microinjection of Ha p21ras was also inhibited by pretreatment of oocytes with Cl-930 or imazodan, with IC50 values of 4.3 +/- 1.2 and 59 +/- 4 microM, respectively. Progesterone-induced maturation was not affected by PDE III inhibitor action; and, neither type IV PDE inhibitors (Ro 20, 1724 or rolipram) nor dipyridamole (a type V PDE inhibitor) inhibited cell division induced by IGF-I or microinjected Ha p21ras. In addition, while insulin-stimulated oocyte PDE activity measured in vivo after microinjection of 200 microM [3H] cAMP was inhibited by nonselective and type III-specific drugs (with IC50 values of 4.2 +/- 1.8 microM Cl-930 and 26 +/- 6 microM imazodan), type IV and type V inhibitors did not inhibit hormone-stimulated enzyme activity. This pharmacological evidence demonstrates a necessary role for PDE III in insulin-, IGF-I-, and p21ras-induced meiotic cell division in Xenopus laevis oocytes.
Sadler
S E
SE
Department of Biological Sciences, University of Denver, Colorado 80208.
D000818:Animals; D000242:Cyclic AMP / Q000494:pharmacology; D005260:Female; D006128:Growth / Q000502:physiology*; D007328:Insulin / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007527:Isoenzymes / Q000378:metabolism / Q000502:physiology*; D008540:Meiosis / Q000187:drug effects / Q000502:physiology; D008845:Microinjections; D015689:Oncogene Protein p21(ras) / Q000494:pharmacology*; D009865:Oocytes / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D009866:Oogenesis / Q000187:drug effects / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism / Q000502:physiology*; D011374:Progesterone / Q000494:pharmacology; D014982:Xenopus laevis
D007328:Insulin; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D011374:Progesterone; D007334:Insulin-Like Growth Factor I; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D015689:Oncogene Protein p21(ras)